US12234282B2ActiveUtilityA1

Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors

74
Assignee: SCHEPENS EYE RES INSTPriority: Mar 5, 2018Filed: May 16, 2023Granted: Feb 25, 2025
Est. expiryMar 5, 2038(~11.6 yrs left)· nominal 20-yr term from priority
Inventors:Dong Feng ChenJi Won MinKin-Sang Cho
A61K 39/395C07K 16/2866A61K 45/06A61K 38/193A61K 9/0048C07K 16/243A61P 27/06A61P 27/02A61K 45/00A61K 2039/505A61K 9/0019A61K 39/3955
74
PatentIndex Score
0
Cited by
64
References
18
Claims

Abstract

The invention provides compositions and methods for treating optic neuropathic disorders.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method for preventing visual function loss in a subject with glaucoma, comprising intravitreally administering to the subject a neutralizing antibody that specifically binds colony stimulating factor-1 receptor (CSF1R). 
     
     
       2. The method of  claim 1 , wherein the antibody specifically binds a portion of CSF1R. 
     
     
       3. The method of  claim 1 , wherein the antibody specifically binds a portion of SEQ ID NO: 1 or 2. 
     
     
       4. The method of  claim 1 , wherein the antibody is administered at least once a day. 
     
     
       5. The method of  claim 1 , wherein the antibody is administered once every second or third day. 
     
     
       6. The method of  claim 1 , wherein the antibody inhibits or reduces the binding of a CSF1R ligand to CSF1R. 
     
     
       7. The method of  claim 6 , wherein the CSF1R ligand is CSF1 or IL-34. 
     
     
       8. The method of  claim 1 , wherein the antibody comprises antibody fragments, Fab, Fab′, F(ab′)2 fragments, Fv fragments, single chain antibodies, humanized antibodies, or combinations thereof. 
     
     
       9. The method of  claim 1 , wherein the antibody comprises RG-7155, FPA-008, M279, or combinations thereof. 
     
     
       10. A method for improving visual function in a subject with glaucoma, comprising intravitreally administering to the subject a neutralizing antibody that specifically binds colony stimulating factor-1 receptor (CSF1R). 
     
     
       11. The method of  claim 10 , wherein the antibody specifically binds a portion of CSF1R. 
     
     
       12. The method of  claim 10 , wherein the antibody specifically binds a portion of SEQ ID NO: 1 or 2. 
     
     
       13. The method of  claim 10 , wherein the antibody is administered at least once a day. 
     
     
       14. The method of  claim 10 , wherein the antibody is administered once every second or third day. 
     
     
       15. The method of  claim 10 , wherein the antibody inhibits or reduces the binding of a CSF1R ligand to CSF1R. 
     
     
       16. The method of  claim 15 , wherein the CSF1R ligand is CSF1 or IL-34. 
     
     
       17. The method of  claim 10 , wherein the antibody comprises antibody fragments, Fab, Fab′, F(ab′)2 fragments, Fv fragments, single chain antibodies, humanized antibodies, or combinations thereof. 
     
     
       18. The method of  claim 10 , wherein the antibody comprises RG-7155, FPA-008, M279, or combinations thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.